Risk factor
Low price volatility
Profitability factor
Strong margins and returns
About
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, over
Target Price
The average target price of YPSN.SW is 397 and suggests 0.789% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t